TRial on the Endocrine Activity of Neoadjuvant Degarelix

PHASE2CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

August 25, 2017

Study Completion Date

August 25, 2017

Conditions
Breast Cancer Invasive Nos
Interventions
DRUG

triptorelin

Triptorelin 3.75 mg injected into the muscle on day 1 every 28 days for 6 cycles (1 cycle= 28 days)

DRUG

degarelix

Degarelix 240 mg injected under the skin given as two injections of 120 mg on the first day of treatment, followed by injection of 80 mg on day 1 of cycles 2 to 6 (1 cycle=28 days)

DRUG

letrozole

Letrozole 2.5 mg orally every day for 6 cycles

Trial Locations (7)

2100

"A.O Ospedale di Circolo e Fondazione Macchi", Varese

16128

Ospedali Galliera, Genova

20141

Istituto Europeo di Oncologia, IEO, Milan

27100

Salvatore Maugeri Fondation, Pavia

40138

Azienda Ospedaliero-Universitaria Policlinico S. Orsola-Malpighi di Bologna, Bologna

47037

Ospedale degli Infermi, Rimini

59100

Istituto Toscana Tumori, Prato

All Listed Sponsors
lead

ETOP IBCSG Partners Foundation

NETWORK

NCT02005887 - TRial on the Endocrine Activity of Neoadjuvant Degarelix | Biotech Hunter | Biotech Hunter